financetom
Business
financetom
/
Business
/
Evergold Closes C$5.4 Million Non-Brokered Private Placement
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Evergold Closes C$5.4 Million Non-Brokered Private Placement
Apr 7, 2026 4:23 AM

06:59 AM EDT, 04/07/2026 (MT Newswires) -- Evergold ( EVGUF ) late on Monday said it has closed a non-brokered private placement financing totaling C$5.4 million.

The offering consists of 6.6 million hard-dollar units at a price of $0.55 per HD unit for gross proceeds of $3.6 million and 2.7 million flow-through shares at a price of $0.65 per FT share for gross proceeds of $1.8 million.

Each HD unit is composed of one common share in the capital of Evergold ( EVGUF ) and one half of one common share purchase warrant. Each HD warrant entitles the holder to acquire one additional common share of Evergold ( EVGUF ) at an exercise price of $0.80 for a 24-month period following the date of issuance.

Each FT share is composed of one common share of Evergold ( EVGUF ) that qualifies as a "flow-through share" as defined in the Income Tax Act (Canada).

The gross proceeds from the issuance of FT shares will be used for "Canadian exploration expenses" on Evergold's ( EVGUF ) Canadian mineral properties, primarily the Golden Lion project, and will qualify either as "flow-through critical mineral mining expenditures" or "flow-through mining expenditures."

The net proceeds from the issuance of the HD units will be primarily used for exploration activities at the company's properties, as well as for general working capital purposes.

Completion of the offering is subject to the receipt of all necessary regulatory approvals, including TSXV approval.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BioMarin Pharmaceutical Secures European Regulatory Approval for Amicus Therapeutics Acquisition
BioMarin Pharmaceutical Secures European Regulatory Approval for Amicus Therapeutics Acquisition
Apr 7, 2026
07:00 AM EDT, 04/07/2026 (MT Newswires) -- BioMarin Pharmaceutical's ( BMRN ) proposed acquisition of Amicus Therapeutics ( FOLD ) has been approved by the European Commission, the regulator said Tuesday. The regulator said the pending transaction raised no competition concerns. Under the deal announced in December, BioMarin will acquire Amicus for $14.50 per share in cash, valuing the company...
Evergold Closes C$5.4 Million Non-Brokered Private Placement
Evergold Closes C$5.4 Million Non-Brokered Private Placement
Apr 7, 2026
06:59 AM EDT, 04/07/2026 (MT Newswires) -- Evergold ( EVGUF ) late on Monday said it has closed a non-brokered private placement financing totaling C$5.4 million. The offering consists of 6.6 million hard-dollar units at a price of $0.55 per HD unit for gross proceeds of $3.6 million and 2.7 million flow-through shares at a price of $0.65 per FT...
World is lining up for Russian energy, the Kremlin says
World is lining up for Russian energy, the Kremlin says
Apr 7, 2026
* Kremlin says there are huge requests for Russian energy * Kremlin says there is a global energy crisis * Europe wants to end its energy purchases from Russia * Yamal LNG sends first cargo to China since November By Dmitry Antonov and Guy Faulconbridge MOSCOW, April 7 (Reuters) - The Kremlin said on Tuesday there were a huge number...
Form 8.3
Form 8.3
Apr 7, 2026
PARIS--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: DNCA FINANCE (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle...
Copyright 2023-2026 - www.financetom.com All Rights Reserved